Company / Return on Equity (ROE)
DNA X, Inc. Return on Equity (ROE) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-0.4%
FY2024
5-year range
-207.3% / -0.4%
FY2020-FY2024
Trend
+99.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
DNA X, Inc. reports negative total equity of -0.4% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-0.4% in FY2024 with a 5-year CAGR of -25.3%.
Improved from -207.3% to -0.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +116.9pp
- 5-Year Change
- -25.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 99.4% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -0.4% | +99.4% |
| FY2023 | -70.3% | +66.1% |
| FY2022 | -207.3% | -76.8% |
| FY2021 | -117.3% | -15.9% |
| FY2020 | -101.2% | -506.5% |
| FY2019 | 24.9% | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026